ROTAVAC®轮状病毒疫苗在越南6-8周龄健康婴儿中的免疫原性、安全性与反应原性
本研究在越南开展Ⅳ期临床试验,纳入360名6-8周龄健康婴儿,完成ROTAVAC®三剂全程接种。接种后抗轮状病毒IgA滴度显著升高(p=0.003),55.4%和48.3%的婴儿分别达到≥3倍和≥4倍抗体增长。接种后30分钟内未记录到不良事件,14天内最常见为发热、异常哭闹和易激惹,未观察到肠套叠病例。
要点
- 完成三剂ROTAVAC®全程接种后,婴儿抗轮状病毒IgA滴度显著升高(p=0.003)。
- 55.4%的婴儿抗体滴度增长≥3倍,48.3%增长≥4倍。
- 常见不良事件为发热、异常哭闹和易激惹,未见肠套叠病例。
核心结论
- ROTAVAC®全程接种在6-8周龄健康婴儿中诱导免疫应答,安全性临床可接受。
- 研究完成后ROTAVAC®已获WHO预认证并在越南上市使用。
研究设计与样本
- 在越南开展的Ⅳ期临床试验,纳入360名6-8周龄健康婴儿,采用ROTAVAC®三剂全程接种方案。
- 入组时平均年龄±标准差为6.9±0.6周,采用酶联免疫吸附试验检测血清抗轮状病毒IgA。
主要发现
- 接种前抗轮状病毒IgA滴度为4.01±3.74 mg/ml,接种后升至29.27±80.64 mg/ml。
- logIgA从0.28±0.79显著升高至1.03±0.54(p=0.003)。
- 接种前后IgA抗体滴度增长≥3倍和≥4倍的受试者比例分别为55.4%和48.3%。
- 每剂接种后30分钟内未记录到不良事件或严重不良事件,每次访视后14天内最常见不良事件为发热、异常哭闹和易激惹。
- 其他不良事件发生率低,未观察到肠套叠病例。
临床怎么用
- 可为6-8周龄婴儿按三剂全程接种ROTAVAC®提供免疫原性与安全性证据支持。
- 接种后应关注发热、异常哭闹和易激惹等常见反应,并持续监测肠套叠等安全性事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ROTAVAC® is derived from human 116E rotavirus (RV) neonatal strain. In this study, we evaluated the immunogenicity, safety and reactogenicity of ROTAVAC® in Vietnam. METHOD: We conducted a phase IV clinical trial in healthy infants aged 6-8 weeks using the complete regimen of ROTAVAC® with three doses. Serum anti-RV IgA was measured by enzyme-linked immunosorbent assay to assess the geometric mean concentration in infants who received the complete regimen of the vaccine. RESULTS: A total of 360 participants were enrolled in this clinical trial. The mean age ± standard deviation at enrollment was 6.9 ± 0.6 weeks. The anti-RV IgA titer was 4.01 ± 3.74 mg/ml pre-vaccination and substantially increased to 29.27 ± 80.64 mg/ml post-vaccination. The value of logIgA significantly increased (p = 0.003) from 0.28 ± 0.79 to 1.03 ± 0.54. The proportion of participants with equal to and greater than 3-fold and 4-fold shifts in pre- to post-vaccination antibody titer (IgA) were 55.4% and 48.3%, respectively. No adverse events or serious adverse events were recorded immediately within 30 min after the administration of each dose. The most common adverse events within 14 days after each visit were fever, unusual crying and irritability. Other adverse events occurred at a low rate, and no case of intussusception was noted. CONCLUSIONS: The complete regimen of ROTAVAC® demonstrated an immunological response with clinically acceptable safety profile. Post-completion of this study, ROTAVAC® is now a WHO-prequalified vaccine and available in Vietnam.
引用
- Hai NM, Dung ND, Pho DC, et al. Immunogenicity, safety and reactogenicity of ROTAVAC® in healthy infants aged 6-8 weeks in Vietnam. Vaccine. 2021. PMID: 33461837. doi:10.1016/j.vaccine.2020.12.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。